Register for free to
view the full innovation profile.
We provide a suite of image analysis tools to explore intestinal transit, motility, fluid and content all with Magnetic Resonance Imaging
About
During my PhD I worked with MRI to look at the gut primarily in inflammatory bowel disease where over 40,000 scans are done every year in the UK. MRI is widely available and increasingly affordable (£<400 per scan) and provides unprecedented insights into gut function. The core problem we address with our innovation (Entrolytics) is managing the quantifying the large volume of data. Why does this matter? If you are interested in how a drug, therapy or intervention works MRI and the way we analyse the data on Entrolytics allows rapid and objective assessment on specific mechanisms of actions. Alternatively, you can use the technology to select and classify patients who otherwise have non-specific symptoms.
Key Benefits
Non invasive and ideal for use in children. Objective and transparent methodology. Well validated and used by internationally recognised centres of excellence. Widely available and we can provide/help with access to research partners. We are highly collaborative and innovative with study design and completion (especially in this COVID era).
Applications
Digestive health is a huge market and Boots is at the forefront of delivering these agents to customers. Our vision of success is providing supporting data to reinforce marketing claims and improve the lives of millions of patients. We have worked already with a number of drugs like Buscopan to assess how it works and on what parts of the intestine. With fibre supplements we can look at intestinal (colonic) water to assess dosing and mechanism of cation. With anti-reflux agents we can examine distribution of eg. alienate or other substance to stop symptoms. In pre-clinical models (animals) perform dose response studies to evaluate mechanism of action for regulatory approvals.